Published in Clin Pharmacol Ther on April 01, 1981
Diagnosis of impaired fetal growth in newborn infants. Pediatrics (1971) 3.62
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
The effect of corneal thickness on applanation tonometry. Am J Ophthalmol (1993) 2.74
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55
Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med (2000) 1.41
Headache syndromes suggested by factor analysis of symptom variables in a headache prone population. J Chronic Dis (1972) 1.33
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Absorption of orally given digoxin preparations. JAMA (1972) 1.27
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25
Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22
Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger (DIP, PIP, and trapeziometacarpal) joints: evidence of clinical efficacy. J Altern Complement Med (2000) 1.14
Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09
Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Postnatal somatic growth in infants with atypical fetal growth patterns. Am J Dis Child (1977) 1.06
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Fetal malnutrition in white newborn infants: maternal factors. Pediatrics (1973) 1.02
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Uric acid excretion in normal children. J Pediatr (1978) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99
Fetal growth retardation in relation to maternal smoking and weight gain in pregnancy. Am J Obstet Gynecol (1976) 0.98
Female gender is a major determinant of changing subsite distribution of colorectal cancer with age. Cancer (1985) 0.98
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93
Drug interactions. Pharmacol Physicians (1970) 0.93
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92
Maternal factors in "fetally malnourished" black newborn infants. Am J Obstet Gynecol (1974) 0.90
Joint moments in minor limb length discrepancy: a pilot study. Am J Orthop (Belle Mead NJ) (1997) 0.90
Recurrent neck disease in oral cancer. J Oral Maxillofac Surg (2002) 0.90
Socioeconomic factors in relation to fetal growth in white infants. J Pediatr (1976) 0.88
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87
The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85
Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis (1977) 0.84
Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos (1981) 0.84
Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther (1975) 0.83
Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci (1974) 0.83
Effects of selected hypolipidemic drugs on cell ultrastructure. Fed Proc (1971) 0.83
Maternal factors in the incidences of low birthweight infants among black and white mothers. Pediatr Res (1978) 0.83
1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator. Res Commun Chem Pathol Pharmacol (1975) 0.82
Metabolic disposition of antipyrine in patients with lung cancer. Cancer Res (1977) 0.82
Pharmacology of hypolipidemic drugs. Introduction. Fed Proc (1971) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther (1978) 0.81
Topical application of lindane cream (Kwell) and antipyrine metabolism. J Invest Dermatol (1980) 0.81
Metabolic responses to plasma concentrations of theophylline. Clin Pharmacol Ther (1979) 0.81
Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography. J Chromatogr (1978) 0.81
Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest (1991) 0.81
Methods to assess relative reliability of diet records: minimum records for monitoring lipid and caloric intake. J Am Diet Assoc (1986) 0.81
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin Pharmacokinet (1990) 0.80
Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions. Clin Toxicol (1971) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
The effect of Perkins, Tono-Pen, and Schiötz tonometry on intraocular pressure. Am J Ophthalmol (1991) 0.80
Species differences in the plasma protein binding of desipramine. J Pharm Pharmacol (1968) 0.79
Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther (1978) 0.79
Serum digitoxin in uremic patients. Clin Pharmacol Ther (1972) 0.79
The effect of DDD on barbiturate and steroid-induced hypnosis in the dog and rat. Biochem Pharmacol (1966) 0.79
Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt. J Pharm Sci (1974) 0.78
Placental transfer and fetal urinary excretion of gentamicin during constant rate maternal infusion. Pediatr Res (1975) 0.78
The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin. Ann N Y Acad Sci (1973) 0.78
Hepatic catalase is not essential for the hypolipidemic action of peroxisome proliferators. Proc Soc Exp Biol Med (1977) 0.78
Effect of buckling material on ocular rigidity. Ophthalmology (1992) 0.78
Inhibition of amphetamine tolerance and metabolism by propranolol. J Pharmacol Exp Ther (1974) 0.77
Maternal smoking and fetal growth of full term infants. Pediatr Res (1974) 0.77
Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic. Am Rev Respir Dis (1973) 0.76
Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm (1982) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
Low dose cyclosporin-A therapy in Behçet's disease. J Ocul Pharmacol (1994) 0.76
Use of clindamycin in patients with liver disease. Antimicrob Agents Chemother (1976) 0.75
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype. J Pharmacokinet Biopharm (1980) 0.75
The effect of hypocholesterolemic drugs on adrenal corticosteroid secretion. Steroids (1967) 0.75
An open-label study of levopromazine (methotrimeprazine) as an add-on therapy in fibromyalgia management. Clin Exp Rheumatol (2010) 0.75